CN112898419B - Monoclonal antibody for detecting highly pathogenic PRRSV (porcine reproductive and respiratory syndrome Virus) and application thereof - Google Patents
Monoclonal antibody for detecting highly pathogenic PRRSV (porcine reproductive and respiratory syndrome Virus) and application thereof Download PDFInfo
- Publication number
- CN112898419B CN112898419B CN202110152893.1A CN202110152893A CN112898419B CN 112898419 B CN112898419 B CN 112898419B CN 202110152893 A CN202110152893 A CN 202110152893A CN 112898419 B CN112898419 B CN 112898419B
- Authority
- CN
- China
- Prior art keywords
- prrsv
- monoclonal antibody
- antibody
- hybridoma cell
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 title claims abstract description 84
- 230000001717 pathogenic effect Effects 0.000 title description 6
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 57
- 238000001514 detection method Methods 0.000 claims abstract description 45
- 238000002965 ELISA Methods 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 21
- 238000004321 preservation Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 12
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- 238000008157 ELISA kit Methods 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 230000003248 secreting effect Effects 0.000 claims description 5
- 241000283707 Capra Species 0.000 claims description 4
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 238000003908 quality control method Methods 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 229960005486 vaccine Drugs 0.000 abstract description 8
- 238000006386 neutralization reaction Methods 0.000 abstract description 6
- 230000009257 reactivity Effects 0.000 abstract description 5
- 230000002238 attenuated effect Effects 0.000 abstract description 3
- 238000011081 inoculation Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 33
- 238000000034 method Methods 0.000 description 24
- 239000000243 solution Substances 0.000 description 19
- 241000700605 Viruses Species 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 206010003445 Ascites Diseases 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 241000282898 Sus scrofa Species 0.000 description 9
- 239000012228 culture supernatant Substances 0.000 description 9
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 241001673669 Porcine circovirus 2 Species 0.000 description 6
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 244000309466 calf Species 0.000 description 6
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241001292005 Nidovirales Species 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000011841 epidemiological investigation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000871677 PRRSV VR2332 Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- -1 monoclonal antibody Proteins 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
Abstract
The monoclonal antibody hybridoma cell strain 3E8 with high specificity and high sensitivity is prepared, the monoclonal antibody secreted by the hybridoma cell strain 3E8, the PRRSV-NVDC-JXA1 strain and the PRRSV-JXA1-R vaccine attenuated strain obtained by passage have good reactivity, have broad-spectrum reactivity for American PRRSV and European PRRSV, and can be used for detection of the American PRRSV and European PRRSV, and meanwhile, the monoclonal antibody can inhibit and reduce CPE caused by inoculation of the PRRSV-NVDC-JXA1 strain, and has certain neutralization activity for PRRSV viruses.
Description
The technical field is as follows:
the invention belongs to the field of biology, and particularly relates to a monoclonal antibody for detecting highly pathogenic PRRSV (porcine reproductive and respiratory syndrome Virus), and a preparation method and application thereof.
Background art:
porcine Reproductive and Respiratory Syndrome (PRRS) is a highly-contact infectious disease mainly characterized by reproductive disorders of pregnant sows and respiratory diseases of piglets, caused by PRRSV (PRRSV), and has the main clinical symptoms of reproductive disorders of pregnant sows, manifested by abortion, stillbirth, mummy and weak fetuses, respiratory diseases of pigs of various ages, particularly piglets, high mortality, immunosuppression, persistent infection and the like, so that the PRRS is one of important infectious diseases which seriously affect the health development of the world pig industry at present, particularly, the high pathogenic Porcine reproductive and respiratory syndrome (HP-PRRS) mainly characterized by high fever, high morbidity and high mortality appears in China and surrounding countries since 2006, and causes great economic loss to the pig industry in China. PRRS is difficult to control mainly because: first, PRRSV infects and spreads silently in a variety of ways, with high infectivity; secondly, the PRRSV is taken as an RNA virus and has high variability, the difference of the antigenic epitopes of different strains is large, and the cross protection of different vaccines is poor, so that the prevention and control become extremely troublesome; thirdly, the PRRSV can be latent in the pig body for a long time, once the immunity of the organism is low, the PRRSV can enter in a deficient state and multiply in a large amount, so that the pig shows clinical symptoms and is further ill.
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) belongs to the order Nidovirales (Nidovirales), the family of arterividae (Arterviridae), the genus of arterivirus (genus Arterviridae), and is a positive-stranded enveloped RNA virus. PRRSV is classified into european type (type i, representing strain LV) and north american type (type ii, representing strain VR 2332), and the genotype of PRRSV circulating in our country is mainly type ii. PRRSV invades the body mainly through two routes, the respiratory system and the reproductive system, thereby destroying the immune system, such as macrophages and monocytes, and sometimes causing death of the body by secondary infections (bacterial and fungal infections). When a diseased pig is infected with PRRSV, the virus proliferates in large numbers in the organism PAM cells, thereby damaging and gradually disrupting PAM cells and mononuclear macrophages, PRRSV homeotropically enters the systemic blood and lymph circulation, causing systemic reactions and possibly triggering viremia.
The virus can invade immune system to cause persistent infection, and is generally prevented and controlled by means of immune vaccine at present, but the epidemic situation of the epidemic disease is increasingly complicated and changeable due to the large amount of vaccine, so that the method for quickly diagnosing the PRRSV is established, and the method has important guiding significance for the PRRS epidemiological investigation and the control of the epidemic disease of swine herds in China. Diagnosis of PRRS is generally divided into etiology and serology. Diagnostic tools for detecting PRRSV are very important, and diagnosis of PRRSV based on-site clinical symptoms is very difficult due to changes in signs of infection. The most common diagnostic tools for diagnosing PRRSV include immunoperoxidase monolayer cell assay (IPMA), enzyme-linked immunosorbent assay (ELISA), real-time fluorescent quantitative RT-PCR, indirect immunofluorescence IFA, serum neutralization assay and the like, but the real-time fluorescent quantitative RT-PCR has high technical content and detection cost, and false positive results easily occur; the antibody detection method is most classic in IDEXX and French LSI in the United states, wherein the Herdchek ELISA detection kit of IDEXX company takes whole viruses as coating antigens, and is generally a standard method for detecting PRRSV antibodies. Researches show that organisms generate antibodies with higher levels in early infection, antibodies aiming at N and M proteins can be detected firstly, the antibody detection method plays an important role in epidemic disease prevention and control, at present, enzyme-linked immunosorbent assay (ELISA) is simple, convenient, quick and sensitive to operate and easy to standardize in a plurality of PRRSV detection methods, and is very suitable for large-scale epidemiological investigation and monitoring. At present, PRRSV antibody detection in China mainly depends on detection kits imported from foreign countries and is expensive, so that establishment of a domestic PRRSV antibody detection method with good specificity and high sensitivity has great significance for PRRSV prevention and control in China, and preparation of a PRRSV monoclonal antibody with high specificity and sensitivity has great significance for PRRSV detection methods and detection kit preparation.
The invention content is as follows:
in order to solve the technical problems, the invention aims to provide a monoclonal antibody for detecting highly pathogenic PRRSV and a preparation method and application thereof, the monoclonal antibody hybridoma cell strain 3E8 with high specificity and high sensitivity is prepared, and the secreted monoclonal antibody has broad-spectrum reactivity for American type PRRSV and European type PRRSV, can be used for detecting the American type PRRSV and the European type PRRSV and has certain neutralization activity for PRRSV virus.
In order to solve the technical problems, the invention adopts the following technical means:
the monoclonal antibody against PRRSV is obtained by secreting a hybridoma cell strain 3E8, wherein the hybridoma cell strain 3E8 is preserved in Guangdong province microbial culture collection center (GDMCC), and the preservation number is as follows: GDMCC No:61302, preservation date is 2020, 11/20/month; the preservation address is as follows: zhou 100 Mr. Yao, guangzhou, guangdong province institute for microorganisms of Guangdong province, no. 59 Lou 5 Lou.
A hybridoma cell strain is named as 3E8 and is preserved in Guangdong province microbial culture collection center (GDMCC), and the preservation number is as follows: GDMCC No:61302, preservation date is 2020, 11 months and 20 days; the preservation address is as follows: guangdong institute for microorganisms, guangdong province, no. 59 building, no. 5 building, miehuo, no. 100, miehuo, guangzhou, china.
The invention also claims the application of the monoclonal antibody in establishing a PRRSV detection method, and the detection method is used for clinical detection or non-clinical laboratory research.
The invention also requests to protect the application of the monoclonal antibody in preparing the ELISA kit for PRRSV detection.
The invention also provides application of the monoclonal antibody in preparation of a colloidal gold test strip for PRRSV detection.
The colloidal gold test strip for detecting the PRRSV is characterized in that the test strip is assembled by adopting the monoclonal antibody as a detection line, a purified rabbit anti-PRRSV polyclonal antibody as a gold-labeled antibody and a goat anti-rabbit IgG as a quality control line.
The ELISA kit for detecting PRRSV is characterized in that the kit takes the monoclonal antibody as a detection antibody, and a rabbit anti-PRRSV polyclonal antibody coats an ELISA plate.
The invention also claims the application of the monoclonal antibody in preparing a medicament for treating PRRSV infection, and the monoclonal antibody has neutralizing activity for PRRSV virus.
Based on the technical scheme, the invention has the following advantages and beneficial effects:
firstly, the monoclonal antibody hybridoma cell strain 3E8 with high specificity and high sensitivity is prepared by taking PRRSV-NVDC-JXA1 preserved by the company as an antigen, the antibody titer in the cell culture supernatant of the hybridoma cell strain is 1.
And secondly, the invention adopts the prepared monoclonal antibody 3E8 and polyclonal antibody to construct an ELISA kit and a detection method for detecting highly pathogenic PRRSV infection, and the ELISA kit can detect the American PRRSV virus which is mainly prevalent at present, is suitable for preventing and controlling the PRRS epidemic situation in China, can detect the European PRRSV virus which is prevalent in the European area, and is suitable for being used as a main detection means of import and export quarantine departments. And tests show that the concentration of the PRRSV-NVDC-JXA1 detected at the lowest level by the kit is 0.05 mu g/mL, the concentration of the PRRSV-DV strain is 0.1 mu g/mL, the consistency with RT-PCR detection is 100%, and compared with the kit reported in the prior art, the kit is more sensitive and accurate.
In conclusion, the monoclonal antibody with high sensitivity and specificity can be used for detecting American type PRRSV and European type PRRSV, and simultaneously, the monoclonal antibody can inhibit and reduce CPE caused by inoculation of PRRSV-NVDC-JXA1 strain, and has certain neutralization activity on PRRSV virus.
Description of the drawings:
FIG. 1: the identification result of the monoclonal antibody, wherein A, PRRSV-NVDC-JXA1 strain (virulent strain); b, PRRSV-JXA1-R vaccine low virulent strain; c, negative control.
FIG. 2 is a schematic diagram: the strain detection activity identification result of the monoclonal antibody, wherein A is negative control; b, PRRSV-NVDC-JXA1 strain (virulent strain); c, PRRSV-GD strain (virulent strain); d, PRRSV-JXA1-R vaccine low virulent strain; e, PRRSV-VR2332; f, PRRSV-DV strain.
FIG. 3: the neutralizing activity of the monoclonal antibody was measured.
FIG. 4: the result of a specific test of ELISA, wherein 1,PRRSV-NVDC-JXA1;2,PEDV;3, CSFV;4,PCV1;5,PCV2;6,PPV;7,PRRSV-DV strain; 8,SPF pig serum.
FIG. 5: a specific test result detected by a colloidal gold test strip, wherein 1,PRRSV-NVDC-JXA1;2,PEDV;3, CSFV;4,PCV1;5,PCV2;6,PPV;7,SPF porcine serum.
The specific implementation mode is as follows:
EXAMPLE 1 establishment, identification and preservation of monoclonal antibody hybridoma cell lines
1.1 preparation of antigen and immunization of Balb/c mice
The invention adopts a PRRSV virus NVDC-JXA1 strain (preserved and provided by Guangdong Yongshu biological pharmacy Co., ltd.) as an immunogen, the PRRSV virus NVDC-JXA1 strain is inoculated into a Marc-145 cell (preserved and provided by Guangdong Yongshu biological pharmacy Co., ltd.), when the cytopathic effect reaches 80-90%, the cell is repeatedly frozen and thawed 3 times at-80 ℃ so that the virus is released from the cell, the cell is centrifuged for 5 minutes at 3000rpm, cell debris is removed, virus liquid is collected, the TCID50 virus price is measured, and the cell is frozen and stored at-70 ℃ for standby after subpackaging.
Adopting a PRRSV virus NVDC-JXA1 strain frozen at-70 ℃ as an immunizing antigen, and diluting the immunizing antigen to 10 ℃ by using sterilized normal saline 6 TCID 50 The virus diluent is mixed and emulsified with equivalent volume of Freund's complete adjuvant (Sigma company) according to the proportion of 1:1, female SPF grade Balb/c mice (purchased from the center of laboratory animals in Guangdong province) are immunized, and are injected subcutaneously at multiple points on the abdomen, and 200 mu L of each mouse is injected; after 14 days, the virus diluted solution is mixed with an equal volume of Freund incomplete adjuvant (Sigma company) according to the proportion of 1:1 for emulsification, and then abdominal subcutaneous multi-point injection is carried out, wherein 200 mu L of each virus is injected; after 14 days, the same procedure was followed for the third immunization. Collecting blood from tail vein 7 days after the third immunization, detecting antibody titer in immune serum by indirect ELISA method, selecting two mice with highest antibody titer, and injecting tail vein for boosting immunization 3 days before fusion, 200 μ L each.
1.2 preparation and screening of hybridomas
(1) Preparation of hybridomas
The spleen of a mouse which is 3 days after the boosting immunization is picked aseptically to prepare a spleen cell suspension, the spleen cell suspension is mixed with mouse myeloma cells (SP 2/0) in a logarithmic growth phase according to the proportion of 10. The specific fusion is as follows: 1mL of fusion agent PEG preheated at 37 ℃ in advance is sucked, the centrifugal tube is gently shaken and is uniformly added within 1min, and the centrifugal tube is immediately placed in a water bath at 40 ℃ for 2min. Then adding 1mL of DMEM culture solution preheated at 37 ℃ in advance into 30S, adding 2mL of preheated DMEM culture solution within 1min, and adding 2miAdding 10mL of preheated DMEM culture solution into n, slightly shaking the centrifuge tube while dropping liquid, centrifuging for 7min at 1000r/min, discarding supernatant, slightly suspending and precipitating cells with 40mL of HAT selection culture solution containing 20% fetal calf serum, mixing well, adding 100 μ L per well into 96-well cell culture plate of feeder layer cells prepared on the previous day, and culturing at 37 deg.C and 5% CO 2 Culturing at saturated humidity, taking out gently after 24h to observe whether the cells are polluted, if the polluted holes appear, adding 1 percent NaOH, and returning the cells to the incubator without pollution to avoid long-term observation outside, thereby easily influencing the growth of the fused cells. After 5 to 7 days, the fused cells were observed for growth by supplementing or replacing the culture medium with 20% FBS HAT medium once (based on the cell growth).
(2) Establishment of Indirect Immunofluorescence (IFA) method
Healthy Balb/c mice of 4-6 weeks old were bred under the same conditions as the immunized mice as negative control mice. The immune mice and the control mice are subjected to blood collection before fusion, and negative and positive serum is separated and stored at the temperature of minus 20 ℃ for later use.
The specific method of indirect immunofluorescence is as follows:
a. culturing Marc-145 cells, reserving a bottle of normal cells without virus inoculation as a negative control, inoculating Marc-145 cells with PRRSV virus NVDC-JXA1 strain, inoculating 150 mu L10. Mu.L of cells in each bottle 6 TCID 50 Virus liquid, at 37 deg.C and 5% CO 2 Culturing in an incubator, preparing digestive cells if 50% -70% of cytopathic effect is observed, sucking out old culture solution in a bottle, adding 1mL of pancreatin digestive juice, and discarding pancreatin after cell gap enlargement and refractivity enhancement are observed by a microscope; directly adding 1mL of culture solution containing serum, terminating digestion of residual pancreatin and repeatedly blowing and sucking to make cells fall off from the wall, transferring the cell suspension into a 2mL EP tube, centrifuging at 2000rpm for 3min; discarding the supernatant, adding 800 μ L PBS, and gently blowing and resuspending by a pipette gun; simultaneously digesting and resuspending normal Marc-145 cells according to the method;
b. preparing a clean glass slide, uniformly coating a cell buffer solution in the holes of the glass slide, fully airing for 1h, fixing the glass slide after sample application by using acetone refrigerated at the temperature of-20 ℃ for 10min, naturally airing, and storing at the temperature of-20 ℃ for later use;
c. taking SP2/0 cell culture supernatant, positive serum of an immune mouse, negative serum of a control mouse and supernatant of hybridoma cells to be detected as primary antibodies, diluting the supernatant by using stock solution and negative and positive serum by using PBS buffer solution, dripping 20 mu L of the supernatant into small holes on a glass slide respectively, paying attention to avoid mutual spread of liquid in the holes, placing the holes in a wet box for incubation, and acting for 30min at 37 ℃;
d. discarding the liquid on the glass slide, washing 3 times with PBS buffer solution, 3min each time, naturally air-drying, diluting the FITC-labeled goat anti-mouse IgG secondary antibody with PBS buffer solution to working concentration (diluted by 100 times), 20 μ L per well, placing in a wet box, incubating in dark, and acting at 37 ℃ for 30min;
e. washing with PBS buffer solution for 3 times, each time for 5min, air drying, adding 50% glycerol, sealing with cover glass, and observing result with fluorescence microscope;
f. the hybridoma cells which are detected to be positive are subjected to rechecking by using a prepared normal Marc-145 cell sheet which is not subjected to toxicity, so that false positive is avoided. (3) Screening and subcloning of hybridoma cells
Screening cell culture supernatant by adopting an indirect ELISA method, selecting strong positive clone hybridoma cells, carrying out subcloning by adopting a limiting dilution method, continuously cloning for 3 times, simultaneously adopting IFA to detect so that the positive rate of the clone cells reaches 100 percent, determining to obtain hybridoma cell strains stably secreting specific monoclonal antibodies, transferring the hybridoma cell strains into a 24-hole plate from a 96-hole plate, continuously carrying out passage to 12-hole and 6-hole cell culture plates, finally carrying out expanded culture in a cell bottle, storing by using liquid nitrogen, and obtaining 3 hybridoma cell strains stably secreting antibodies in total, wherein the hybridoma cell strains are respectively 1G4, 3E8 and 5D2.
1.3 Performance assay of hybridoma cell lines
(1) Stability characterization of hybridoma cells
Freezing and restoring the 3 screened hybridoma cell strains, continuously subculturing for 20 generations, collecting cell culture supernatant, and detecting the antibody level by using an IFA method, wherein the results are shown in the following table 1:
TABLE 1 stability identification of hybridoma cells
The results in table 1 show that, in the 3 hybridoma cell lines obtained by the invention, the 1G4 and 3E8 have stable monoclonal antibody secretion capacity, but the monoclonal antibody secretion capacity of the 5D2 hybridoma cell line is reduced along with cryopreservation and passage, and the antibody titer is reduced; the antibody secretion capacity of 3E8 is enhanced along with passage purification, when the antibody is passed for 20 generations, the antibody titer reaches 1.
(2) Detection of monoclonal antibody titer of hybridoma cell strain
Respectively carrying out passage on the hybridoma cell strain 3E8, the hybridoma cell strain 1G4 and the hybridoma cell strain 5D2 for 20 generations, selecting 5 healthy Balb/c mice with the age of 8-10 weeks as a group, injecting 500 mu L Freund incomplete adjuvant into the abdominal cavity of each mouse, after 7 days, selecting the hybridoma cell strain 3E8, the hybridoma cell strain 1G4 and the hybridoma cell strain 5D2 with good passage culture state for counting, and injecting about 10 percent of Freund incomplete adjuvant into the abdominal cavity of each mouse 6 (ii) individual hybridoma cells; after 7 to 14 days, observing that when the abdomen of the mouse is raised, the ascites in the mouse is slowly sucked out by a disposable syringe, and the ascites can be sucked for a plurality of times according to the induction condition in the mouse, and after collection, the ascites is centrifuged to remove impurities such as fat and the like, and is frozen at the temperature of minus 20 ℃ for standby.
The titer of hybridoma cell culture supernatants and ascites fluids was assayed by the indirect Immunofluorescence (IFA) method with reference to (3), and the hybridoma cell culture supernatants were diluted by 1, 8,1, 16,1. The highest dilution identified as positive was finally determined as IFA titer. The results are given in table 2 below:
TABLE 2 monoclonal antibody titers in hybridoma cell culture supernatants and ascites
| Hybridoma cell strain | Supernatant titer after passage 20 generations | Ascites titer of hybridoma |
| 1G4 | 1:128 | 1:5120 |
| 3E8 | 1:512 | 1:20480 |
| 5D2 | 1:32 | 1:2560 |
Based on the results in table 2 above, it can be seen that in the 3 hybridoma cell lines obtained by the present invention, the 1G4 and 3E8 have strong ability to secrete monoclonal antibodies, wherein the hybridoma cell line 3E8 has the strongest ability to secrete monoclonal antibodies, the antibody titer in the cell culture supernatant reaches 1.
(3) Subtype identification of monoclonal antibodies
The subtype determination of the monoclonal antibody in the ascites purified from the hybridoma cell strain 3E8 was carried out by using a subtype determination kit of sigma, and it was determined that the monoclonal antibody belongs to the IgG1 subclass and the light chain is a kappa chain.
(4) Monoclonal antibody identification
The method comprises the steps of infecting Marc-145 cells with PRRSV strain PRRSV-NVDC-JXA1 (virulent strain) preserved by Guangdong Yongshun biopharmaceutical GmbH of the company, and PRRSV-JXA1-R vaccine attenuated strain (attenuated vaccine production strain of the company) obtained by passage, taking non-virulent Marc-145 cells, mouse negative serum and SP2/0 cell supernatant as negative controls, taking hybridoma cell strain 3E8 culture supernatant as positive control, analyzing the reaction condition of monoclonal antibodies secreted by hybridoma cell strain 3E8 and PRRSV strains, and obtaining specific results as shown in figure 1.
Based on the results shown in FIG. 1, the monoclonal antibody secreted by the hybridoma cell strain 3E8 has good reactivity with the PRRSV-NVDC-JXA1 strain and the PRRSV-JXA1-R vaccine attenuated strain obtained by passage.
(5) Preservation of hybridoma cell lines
Through the tests, the hybridoma cell strain 3E8 with high titer and good specificity to PRRSV antibody is obtained, and is used for storing biological materials of patent programs in Guangdong province microbial strain collection center (GDMCC), and the storage numbers are as follows: GDMCC No:61302, named as Mus musculus hybridoma GDWS F5, classified and named as Mus musculus hybridoma; the preservation date is 2020, 11 months and 20 days; the preservation address is as follows: guangdong institute for microorganisms, guangdong province, no. 59 building, no. 5 building, miehuo, no. 100, miehuo, guangzhou, china. Example 2: preparation and purification of hybridoma cell strain 3E8 monoclonal antibody ascites
2.1 in vivo induced ascites method for preparing monoclonal antibody
Selecting female Balb/c mice in childbirth, injecting 500 mu L of sterilized paraffin into the abdominal cavity, injecting the obtained monoclonal hybridoma cell 3E8 into the abdominal cavity again after one week, wherein the injection amount is 10 6 After one week, ascites is extracted after the abdomen of the mouse is enlarged, the supernatant is centrifuged, and the ascites is purified by a saturated ammonium sulfate method.
2.2 purification of ascites fluid of monoclonal antibody (saturated ammonium sulfate method) and potency measurement
(1) And (3) taking crude monoclonal antibody ascites, adding PBS with the same volume and pH =7.4, and gently mixing the two solutions.
(2) Placing on a shaking table, rotating at room temperature, slowly and dropwise adding saturated ammonium sulfate solution with equal volume to reach saturation of 50%, at this time, a large amount of white precipitate appears, and standing at room temperature for 30min.
(3) Centrifuging at 12000rpm at 4 deg.C for 10min, discarding supernatant, resuspending the precipitate with PBS, placing on a shaker, slowly adding saturated ammonium sulfate to reach 35% saturation, and standing at room temperature for 30min.
(4) And (4) repeating the step (3).
(5) Centrifuge at 12000rpm for 20min at 4 deg.C, discard the supernatant, and resuspend the pellet with PBS.
(6) Putting the antibody solution into a dialysis bag with a proper length, taking physiological saline filtered by a filter membrane with the diameter of 0.22 μm as dialysate, putting the dialysate into a rotor rotating liquid, and dialyzing for 24h at the temperature of 4 ℃, wherein the dialysate is frequently replaced.
(7) Collecting antibody, measuring and recording antibody titer by indirect ELISA method, subpackaging at 4 deg.C, and storing at-80 deg.C.
Example 3: activity characterization of monoclonal antibodies
(1) Strain detection activity identification of monoclonal antibody
The monoclonal antibody secreted by the hybridoma cell strain 3E8 obtained by analysis and purification is used for reacting with each strain of PRRSV, and specific results are shown in figure 2, wherein the specific results are shown in the figure 2.
Based on the results shown in fig. 2, it can be seen that the monoclonal antibody secreted by the hybridoma cell strain 3E8 of the present invention reacts with all PRRSV strains, and thus the monoclonal antibody of the present invention has broad-spectrum reactivity against both american-type PRRSV and european-type PRRSV.
(2) Determination of neutralizing Activity of monoclonal antibodies
Diluting the purified monoclonal antibody to the titer of 1 12800, then carrying out a virus neutralization test on the monoclonal antibody secreted by the hybridoma cell line 3E8 to detect the neutralization activity, tiling Marc-145 cells to a 24-well plate, and inoculating virus liquid, wherein a positive control group adopts 10 6 TCID 50 Mixing virus solution (PRRSV-NVDC-JXA 1 strain) with PBS buffer solution according to 1:1, and using 10 in experimental group 6 TCID 50 The virus solution (PRRSV-NVDC-JXA 1 strain) and the monoclonal antibody diluent are mixed according to 1:1, PBS buffer solution is adopted as a negative control group, and the neutralization activity is determined by observing the cytopathic condition, and the specific result is shown in figure 3. Based on the results shown in FIG. 3, it can be seen that the monoclonal antibody of the present invention can inhibit and reduce CPE caused by inoculation of PRRSV-NVDC-JXA1 strain, and has a certain neutralizing activity against PRRSV virus.
Example 4: establishment of ELISA detection method
4.1 preparation of polyclonal antibodies against PRRSV:
culturing a PRRSV-NVDC-JXA1 strain by using Marc-145 cells, taking the PRRSV purified by ultracentrifugation as an antigen, fully emulsifying the antigen with Freund's complete adjuvant, performing subcutaneous point injection to immunize 60-day-old rabbits (5 mg antigen/rabbit), fully emulsifying the same antigen with Freund's incomplete adjuvant respectively for 15 days and 30 days, then performing boosting immunization once respectively, after 45 days, collecting whole body blood by carotid intubation, standing overnight at 4 ℃, centrifuging 3000g for 15min, separating and collecting serum; the polyclonal antibody against PRRSV is obtained by Protein G affinity chromatography purification and concentrated to 5mg/mL.
4.2 Establishment of ELISA detection method
The PRRSV-ELISA detection method is established by referring to the method in the patent application CN201010252436.1 (Yangzhou university, publication No. CN 101915846A), the invention adopts polyclonal antibody to carry out coating, so that the established method can identify PRRSV strains more widely, and the invention also carries out the following tests:
4.2.1 determination of optimal working concentrations of monoclonal and polyclonal antibodies
(1) Coating: using carbonate coating solution to perform gradient dilution on the anti-PRRSV polyclonal antibody, 100 mu L/hole, coating for 2h at 37 ℃, and then standing overnight at 4 ℃; gently throwing out liquid in the holes, washing with PBST cleaning solution for 3 times, and patting dry on absorbent paper every time for 5 min;
(2) And (3) sealing: blocking with 10% calf serum as blocking agent at 200 μ l/well at 37 deg.C for 2h, washing with PBST washing solution for 3 times, and drying;
(3) Adding an antigen: adding purified PRRSV virus and negative cell antigen into an ELISA plate at the same concentration (5 mug/ml) at intervals by using a diluent, performing action at 37 ℃ for 30min by using 100 mug/hole while setting a PBS blank control, washing for 3 times by using PBST washing liquid, and patting to dry;
(4) Adding a monoclonal antibody: diluting monoclonal antibody 3E8 with diluent, adding into enzyme labeling plate, making 100 μ l hole, setting PBS blank control, acting at 37 deg.C for 30min, washing with PBST cleaning solution for 3 times, and patting to dry;
(5) Adding an enzyme-labeled secondary antibody: adding diluted HRP-goat anti-mouse IgG, acting at 37 deg.C for 30min, washing with PBST washing solution for 3 times, and drying;
(6) Color development and termination: adding 100 mul of TMB color development liquid, keeping out of the sun at room temperature for 10-15 min, adding 2M H 2 SO 4 50 μ l/well, OD read on microplate reader 450 . When the OD value of the positive hole is close to 1,P/N value, the concentration combination of the monoclonal antibody and the polyclonal antibody is the optimal working concentration.
According to the determination of a square matrix test, when the combination of the monoclonal antibody 3E8 and the anti-PRRSV polyclonal antibody is adopted, the maximum P/N value is 13.28 when the monoclonal antibody amount is 100ng and the polyclonal antibody coating amount is 500 ng.
TABLE 3 determination of optimal working concentrations of monoclonal and polyclonal antibodies
4.2.2 determination of optimal blocking solution
ELISA assays were performed with 4% gelatin-PBST, 1% BSA-PBST, 5% skim milk-PBST, 5% calf serum-PBST and 10% calf serum-PBST as blocking agents, respectively, according to the determined optimal working concentration combinations of monoclonal and polyclonal antibodies. After different sealing liquids act, the P/N values are different, wherein the result of the calf serum as the sealing liquid is obviously superior to that of other sealing liquids, and the sealing effect (P/N value is 13.15) of 10% calf serum is superior to that of 5% calf serum (P/N value is 8.31).
4.2.3 determination of optimal seal time
And performing ELISA detection by adopting different blocking times (60 min, 90min and 120 min) according to the determined optimal working concentration combination of the monoclonal antibody and the polyclonal antibody and the blocking solution, wherein the effect is optimal when the blocking time is 90min (the P/N value is 13.49).
4.2.4 determination of the action time of the detection antigen, monoclonal antibody, enzyme-labeled antibody
After the optimal working concentration combination, the confining liquid and the confining time of the ELISA monoclonal antibody and the polyclonal antibody are determined, ELISA detection is carried out on the detection antigen, the monoclonal antibody and the enzyme-labeled antibody by adopting different action times. The difference of the P/N values of different action times is not obvious, the CN201010252436.1 time is referred, and the result is obtained by quick sensitivity in clinical application, so the action time of 30min is more suitable.
4.2.5 establishment of Positive and negative criteria
When 50 negative samples are detected by the ELISA method established above, the average OD value of the negative samples is 0.17, and the standard deviation SD is 0.025, so that the positive judgment standard is 0.245 calculated by the mean OD value +3 times SD, namely the OD value of the detection sample is more than 0.245, and the detection sample can be judged to be positive.
4.3 Specific assay for ELISA
ELISA detection is carried out by using PRRSV-NVDC-JXA1, PEDV, CSFV, PCV1, PCV2, PPV and PRRSV-DV strains produced and used by the company as detection antigens, wherein the detection results of the PEDV, CSFV, PCV1, PCV2 and PPV are negative, and the detection results of the PRRSV-NVDC-JXA1 and the PRRSV-DV are positive, and the specific results are shown in the following table 4 and figure 4:
TABLE 4 specificity test of ELISA
| Virus | PRRSV-NVDC-JXA1 | PEDV | CSFV | PCV1 |
| OD | 1.682 | 0.052 | 0.055 | 0.042 |
| Virus | PCV2 | PPV | PRRSV-DV strains | SPF pig serum |
| OD | 0.046 | 0.041 | 0.976 | 0.032 |
The results show that the ELISA method established by the invention has good specificity on PRRSV, can effectively detect American type PRRSV and European type PRRSV, and has no response on common viruses such as classical swine fever virus and diarrhea virus of pigs.
4.5 ELISA sensitivity test
The purified PRRSV-NVDC-JXA1 and PRRSV-DV strains are respectively diluted into different concentrations in a continuous multiple ratio, the lowest detection amount is detected by an established ELISA method, and a negative control is set in the operation process, so that the result shows that the concentration of the purified PRRSV-NVDC-JXA1 detected in the established ELISA test is 0.05 mu g/mL, and the concentration of the PRRSV-DV strains is 0.1 mu g/mL.
4.6 clinical sample testing
100 parts of clinically collected pig lung or lymph node samples are respectively detected by the ELISA method and the RT-PCR method. The ELISA method shows that 59 positive samples exist, the RT-PCR detection result is that the 59 positive samples exist, and the coincidence rate of the two is 100%.
Example 5: application of monoclonal antibody 3E8 in colloidal gold test strip detection method
And (3) adopting the purified 3E8 monoclonal antibody as a detection line, adopting the purified rabbit anti-PRRSV polyclonal antibody as a gold-labeled antibody, and adopting goat anti-rabbit IgG as a quality control line, and assembling the test strip. The test strip can specifically react with PRRSV, and has no cross reaction with PEDV, CSFV, PCV1, PCV2, PPV and the like, and the specific result is shown in figure 5.
The above is only a preferred embodiment of the present invention, and a person skilled in the art can make several modifications and refinements without departing from the technical principle of the present invention, and these modifications and refinements should be regarded as the protection scope of the present invention.
Claims (8)
1. The monoclonal antibody against PRRSV is obtained by secreting a hybridoma cell strain 3E8, wherein the hybridoma cell strain 3E8 is preserved in Guangdong province microbial culture collection center (GDMCC), and the preservation number is as follows: GDMCC No:61302, preservation date is 2020, 11 months and 20 days; the preservation address is as follows: the monoclonal antibody has neutralizing activity against PRRSV virus, and can be used in the research institute of microorganism in Guangdong province, no. 59 building, guangdong province, large institute of Middledo No. 100, middledo, guangzhou, guangdong province.
2. The hybridoma cell strain secreting the monoclonal antibody of claim 1, wherein the hybridoma cell strain is named as 3E8 and deposited in the Guangdong province culture Collection of microorganisms (GDMCC), and the preservation number is: GDMCC No:61302, preservation date is 2020, 11 months and 20 days; the preservation address is as follows: guangdong institute for microorganisms, guangdong province, no. 59 building, no. 5 building, miehuo, no. 100, miehuo, guangzhou, china.
3. Use of the monoclonal antibody of claim 1 for establishing a PRRSV detection method for use in non-clinical laboratory studies.
4. The use of the monoclonal antibody of claim 1 in the preparation of an ELISA kit for PRRSV detection.
5. The use of the monoclonal antibody of claim 1 in the preparation of a colloidal gold test strip for detecting PRRSV.
6. A colloidal gold test strip for detecting PRRSV is characterized in that the test strip is assembled by using the monoclonal antibody in claim 1 as a detection line, using a purified rabbit anti-PRRSV polyclonal antibody as a gold-labeled antibody and using goat anti-rabbit IgG as a quality control line.
7. An ELISA kit for detecting PRRSV, characterized in that the kit uses the monoclonal antibody in claim 1 as a detection antibody, and uses rabbit anti-PRRSV polyclonal antibody to coat an ELISA plate.
8. Use of a monoclonal antibody according to claim 1 having neutralizing activity against PRRSV virus for the manufacture of a medicament for the treatment of PRRSV infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110152893.1A CN112898419B (en) | 2021-02-03 | 2021-02-03 | Monoclonal antibody for detecting highly pathogenic PRRSV (porcine reproductive and respiratory syndrome Virus) and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110152893.1A CN112898419B (en) | 2021-02-03 | 2021-02-03 | Monoclonal antibody for detecting highly pathogenic PRRSV (porcine reproductive and respiratory syndrome Virus) and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112898419A CN112898419A (en) | 2021-06-04 |
| CN112898419B true CN112898419B (en) | 2022-11-08 |
Family
ID=76122106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110152893.1A Active CN112898419B (en) | 2021-02-03 | 2021-02-03 | Monoclonal antibody for detecting highly pathogenic PRRSV (porcine reproductive and respiratory syndrome Virus) and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112898419B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101915846A (en) * | 2010-08-13 | 2010-12-15 | 扬州大学 | ELISA kit for detecting porcine reproductive and respiratory syndrome virus and using method |
| CN101955531A (en) * | 2009-07-17 | 2011-01-26 | 南方医科大学 | Antibody for detecting porcine reproductive and respiratory syndrome virus |
| CN101979512A (en) * | 2010-09-13 | 2011-02-23 | 中国动物疫病预防控制中心 | Anti-porcine reproductive and respiratory syndrome virus monoclonal antibody and application |
-
2021
- 2021-02-03 CN CN202110152893.1A patent/CN112898419B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101955531A (en) * | 2009-07-17 | 2011-01-26 | 南方医科大学 | Antibody for detecting porcine reproductive and respiratory syndrome virus |
| CN101915846A (en) * | 2010-08-13 | 2010-12-15 | 扬州大学 | ELISA kit for detecting porcine reproductive and respiratory syndrome virus and using method |
| CN101979512A (en) * | 2010-09-13 | 2011-02-23 | 中国动物疫病预防控制中心 | Anti-porcine reproductive and respiratory syndrome virus monoclonal antibody and application |
Non-Patent Citations (1)
| Title |
|---|
| 猪繁殖与呼吸综合征病毒N蛋白单克隆抗体的制备与鉴定;于洁;《中国兽医科学》;20190316;第49卷(第7期);第821-827页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112898419A (en) | 2021-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101825633B (en) | Competitive ELISA kit for detecting african swine fever virus antibody and purposes thereof | |
| CN102608315A (en) | Enzyme linked immunosorbent assay kit for porcine pseudorabies virus gE protein antibody and application thereof | |
| CN103059132B (en) | Monoclonal antibody of anti-H9 subtype flu virus haemagglutinin protein and application thereof | |
| CN103266088A (en) | H7 subtype avian influenza virus monoclonal antibody of and kit | |
| CN105296441A (en) | Bovine viral diarrhea virus strain and application thereof | |
| CN107475203A (en) | A kind of H7 avian influenza virus monoclonal antibody and application | |
| CN102747044B (en) | Hybridoma cell line of a kind of resisting pstudorabies virus and preparation method thereof and a kind of monoclonal antibody and application thereof | |
| CN107449912B (en) | Anti- H7N9 subtype avian influenza virus monoclonal antibody antigen epitope and its screening technique and application | |
| CN105348372A (en) | Method for detecting porcine pseudorabies virus | |
| CN101597334A (en) | Monoclonal antibody of bluetongue virus (BTV) and preparation method and application | |
| CN106841609A (en) | A kind of porcine circovirus 2 type blocking ELISA antibody assay kits and preparation method thereof | |
| CN108148814B (en) | Double-antibody sandwich ELISA diagnostic kit for detecting bovine rotavirus and application thereof | |
| CN104120109A (en) | ELISA blocking kit for detecting infectious bovine rihinotracheitis virus gB antibody and application of kit | |
| CN103243077A (en) | Avian leukosis P27 monoclonal antibody hybridoma cell strain and application thereof | |
| CN100376671C (en) | Hybridized tumour cell strain of anti hpatitis B virus surface antigen and its monoclonal antibody | |
| CN112898419B (en) | Monoclonal antibody for detecting highly pathogenic PRRSV (porcine reproductive and respiratory syndrome Virus) and application thereof | |
| CN107831309A (en) | A kind of porcine pseudorabies virus gE protein antibodies competitive ELISA detection kits and detection method | |
| CN105445457B (en) | Detect the monoclonal antibody and kit of carrying Cap gene of porcine circovirus type 2 | |
| CN104911150B (en) | The foundation of monoclonal antibody hybridoma cell strain and its preparation and application of monoclonal antibody of a kind of H3N2 canine influenza virus | |
| CN106699879A (en) | Establishment method and application of type-A avian influenza specific monoclonal antibody | |
| CN112946285B (en) | ELISA kit for detecting highly pathogenic PRRSV infection | |
| CN107653231B (en) | Duck-origin coronavirus low-virulent strain IBVDCV35 and application thereof | |
| CN105543177A (en) | Hybridoma cell strain secreting citrus yellow vein clearing virus-resistant monoclonal antibodies and monoclonal antibody application thereof | |
| CN104965083A (en) | Kit for detecting H3N2 subtype canine influenza virus | |
| CN105198969A (en) | B-cell epitope of VP(viral protein)3 of DHAV (duck hepatitis A virus)-1 as well as identification method and application of B-cell epitope |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |